Chameleon BioSurfaces
Provider of sophisticated surface design technology to medical device companies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Chameleon BioSurfaces Ltd. was a UK-based company that developed advanced polymer coatings for implantable medical devices. The company emerged as a spin-out from the John Innes Centre in Norwich, UK. One of the founding scientists and the director of research was Chris Pickett, who was previously the Associate Head of the Biological Chemistry Department at the John Innes Centre. The company's business focused on providing sophisticated surface design technology to medical device manufacturers. Its primary clients were medical device companies and healthcare institutions that required innovative surface technologies for their products.
Chameleon BioSurfaces' core business involved the use of a patented electrodeposition process to apply proprietary polymer coatings directly onto the surface of medical implants. This technology was developed for devices such as drug-eluting stents and neurostimulators. The coatings were designed to improve biocompatibility, electrical performance, and enable controlled drug release. A key feature was the ability to polymerize the coatings directly from the metal surface, which allowed for the creation of multiple, precisely deposited layers, each providing a specific property. The polymers could be tailored for different types of drugs, including cationic, anionic, and neutral ones. This process ensured complete coverage of complex surfaces and precise control over coating thickness.
In March 2011, all significant assets of Chameleon BioSurfaces were acquired by Biotectix, LLC, an Ann Arbor, Michigan-based company. Biotectix, which was developing a complementary class of conductive polymer materials, integrated Chameleon's technology to enhance its intellectual property position and expand its material offerings for co-development partners in the medical device field. Following the acquisition, all of Chameleon's materials technology and ongoing projects were transferred to Biotectix's facility in Ann Arbor. Keywords: polymer coatings, medical devices, drug eluting stents, surface technology, electrodeposition, biocompatibility, drug delivery, neurostimulators, medical implants, surface design, advanced materials, biomedical applications, John Innes Centre, Chris Pickett, Biotectix, medical device coatings, controlled drug release, implantable devices, surface modification, biomaterials